Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.

Kraft CS, Sims M, Silverman M, Louie TJ, Feuerstadt P, Huang ES, Khanna S, Berenson CS, Wang EEL, Cohen SH, Korman L, Lee C, Kelly CR, Odio A, Cook PP, Lashner B, Ramesh M, Kumar P, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L, Pardi DS, ECOSPOR III and ECOSPOR IV investigators

Open source

DOI: 10.1007/s40121-024-01007-z
Published: 2024 Oct
Container: Infectious diseases and therapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40121-024-01007-z,
  title = {Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.},
  author = {Kraft CS and Sims M and Silverman M and Louie TJ and Feuerstadt P and Huang ES and Khanna S and Berenson CS and Wang EEL and Cohen SH and Korman L and Lee C and Kelly CR and Odio A and Cook PP and Lashner B and Ramesh M and Kumar P and De A and Memisoglu A and Lombardi DA and Hasson BR and McGovern BH and von Moltke L and Pardi DS and ECOSPOR III and ECOSPOR IV investigators},
  year = {2024},
  journal = {Infectious diseases and therapy},
  doi = {10.1007/s40121-024-01007-z},
  url = {https://doi.org/10.1007/s40121-024-01007-z}
}

RIS

TY  - JOUR
TI  - Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
AU  - Kraft CS
AU  - Sims M
AU  - Silverman M
AU  - Louie TJ
AU  - Feuerstadt P
AU  - Huang ES
AU  - Khanna S
AU  - Berenson CS
AU  - Wang EEL
AU  - Cohen SH
AU  - Korman L
AU  - Lee C
AU  - Kelly CR
AU  - Odio A
AU  - Cook PP
AU  - Lashner B
AU  - Ramesh M
AU  - Kumar P
AU  - De A
AU  - Memisoglu A
AU  - Lombardi DA
AU  - Hasson BR
AU  - McGovern BH
AU  - von Moltke L
AU  - Pardi DS
AU  - ECOSPOR III and ECOSPOR IV investigators
PY  - 2024
JO  - Infectious diseases and therapy
DO  - 10.1007/s40121-024-01007-z
UR  - https://doi.org/10.1007/s40121-024-01007-z
ER  -

APA

CS, K., M, S., M, S., TJ, L., P, F., ES, H., S, K., CS, B., EEL, W., SH, C., L, K., C, L., CR, K., A, O., PP, C., B, L., M, R., P, K., A, D., A, M., DA, L., BR, H., BH, M., L, V. M., DS, P., & investigators, E. I. A. E. I. (2024). Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.. Infectious diseases and therapy. https://doi.org/10.1007/s40121-024-01007-z

Source records

pubmed · retrieved 2026-09-25T18:18:24.733Z